SEOM clinical guideline for treatment of kidney cancer (2017)
Clin. transl. oncol. (Print)
; 20(1): 47-56, ene. 2018. tab
Article
en En
| IBECS
| ID: ibc-170467
Biblioteca responsable:
ES1.1
Ubicación: BNCS
ABSTRACT
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge (AU)
RESUMEN
No disponible
Texto completo:
1
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Carcinoma de Células Renales
/
Neoplasias Renales
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Guideline
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Año:
2018
Tipo del documento:
Article